Review the following patient summaries describing complex depressive presentations. Match each clinical profile with the most appropriate next step in pharmacologic or somatic management.
- An 82-year-old male with 2 months of severe depressed mood who now refuses all food and liquids, stating his intestines have completely rotted away.Urgent administration of electroconvulsive therapy (ECT)
- A 22-year-old female with anhedonia and hypersomnia whose history includes a distinct 4-day episode of racing thoughts, decreased need for sleep, and impulsive spending that did not impair functioning.Initiation of quetiapine monotherapy
- A 35-year-old female with chronic depression, prominent mood reactivity, hyperphagia, and severe rejection sensitivity who has failed sequential trials of fluoxetine, venlafaxine, and nortriptyline.Initiation of phenelzine following a strict medication washout protocol
- A 45-year-old male whose depressed mood and active suicidality resolved on maximum-dose sertraline, but who currently struggles with profound residual daytime fatigue, apathy, and cognitive slowing.Augmentation with bupropion
Answer
Match each clinical profile to its targeted therapy based on specific symptom clusters, psychiatric comorbidities, and urgency: the actively starving psychotic patient requires ECT; the patient with past hypomania requires quetiapine for bipolar II depression; the treatment-resistant patient with atypical features benefits from an MAOI; and the patient with residual SSRI-induced apathy requires bupropion augmentation.
Each pairing tests a specific, advanced nuance in the algorithmic treatment of depressive disorders. Patients with severe psychotic depression and refusal to eat require immediate somatic intervention (ECT) to prevent death from dehydration or starvation. Patients presenting with depression who have a history of 4 or more days of elevated mood and energy meet criteria for Bipolar II disorder; they must be treated with bipolar-specific agents (e.g., quetiapine, lurasidone) rather than traditional antidepressants to prevent mood destabilization. Treatment-resistant depression with classic atypical features (mood reactivity, hyperphagia, leaden paralysis, rejection sensitivity) shows unique responsiveness to monoamine oxidase inhibitors (MAOIs) like phenelzine, which remain a high-yield salvage therapy for this subtype. Finally, patients who achieve remission of core depressive and suicidal symptoms on an SSRI but suffer from residual fatigue, cognitive slowing, or apathy benefit from the targeted addition of bupropion, an NDRI that addresses these specific dopaminergic/noradrenergic deficits.
Step-by-Step Solution
Key Concept
Advanced tailoring of pharmacologic and somatic management for depressive disorders based on severity, subtype (psychotic, atypical), comorbidities (bipolarity), and residual symptoms.